Skip to Content


Office of the Director, National Institutes of Health; Meeting

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: September 25-26, 2000.

Time: 9 a.m. to 5 p.m.

Agenda: Discussions of the report from the ACD Working Group on NIH Oversight of Clinical Gene Transfer Research; review of selected human gene transfer protocols; discussions of NIH policy on serious adverse event reporting; data management activities related to human gene transfer clinical trials, and other matters to be considered by the Committee. Additional information will be posted at​od/​oba/​ on the internet.

Place: National Institutes of Health, Building 31, C Wing, Conference Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Eugene Rosenthal, Biotechnology Program Advisor, Office of Biotechnology Activities, National Institutes of Health, MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, MD 20892-7010, Telephone 301-496-9838, Fax 301-496-9839.

Start Signature

OMB's “Mandatory Information Requirements for Federal Assistance Program Announcements” (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Dated: August 15, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

End Signature End Preamble

[FR Doc. 00-21359 Filed 8-21-00; 8:45 am]